NEW YORK (GenomeWeb) – Illumina reported after the close of the market on Tuesday that its third quarter 2017 revenues rose 18 percent year over year.
The San Diego, California-based genomic analysis firm reported total revenues of $714.0 million, up from $607.1 million in the third quarter of 2016. It beat analysts' average estimate of $692.8 million.
Illumina's Q3 2017 product revenue was $596.0 million, up 16 percent from $513.7 million in Q3 2016. Service and other revenue grew 26 percent to $118.0 million from $93.4 million.